+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global Macrolide Antibiotics Market Size was valued at USD 50.7 billion in 2022. The Macrolide Antibiotics market industry is projected to grow from USD 57.67 Billion in 2023 to USD154.33 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.20% during the forecast period (2023 - 2032). The rising prevalence of skin infections, an increase in the need for drugs to treat bacterial skin infections, and rapid antibiotic growth,are the key market drivers enhancing the market growth.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
The treatment of bacterial infections and other conditions has made considerable use of a well-known class of antimicrobial medications known as macrolide antibiotics. Due to the rising incidence of bacterial illnesses worldwide and the increased demand for macrolides, sales of macrolides agents aid in the fight against numerous bacterial infections. The emergence of bacterial strains that are multidrug resistant and the extra advantages macrolides have over conventional antibiotics have both contributed to the realization that macrolides are more effective. This element has an impact on the sales of macrolides in the current market.
Macrolides saw a surge in sales in certain parts of the world as a result of a shorter period of patent exclusivity for new therapeutic applications in the pharmaceutical business as a result of less government involvement in the approval of patents in the drug or pharmaceutical sector. It has been discovered that people today are more protective of and concerned with their health than they were in the past. The increasing patient awareness, health consciousness, and medical spending affect macrolide sales in both established and emerging regions. As a result, infrequently, customers who abuse or use expired macrolides may suffer liver damage. This adverse effect might reduce macrolide sales, which might reduce demand for macrolides for the expected time period. Despite the fact that this is a minor issue, manufacturers can address it by raising customer knowledge and informing them about the expiration date and the negative consequences of utilizing expired macrolides. By doing this, we can assist businesses in boosting macrolides' market share while minimizing side effects.Thus, driving the Macrolide Antibiotics market revenue.
The global Macrolide Antibiotics market segmentation,based on drugs includesAzithromycin, Clarithromycin, Erythromycin, Fidaxomicin, Telithromycin. With 25% of market revenue (18.48 billion) coming from the azithromycin sector, the market was dominated by this product. due to the fact that it has broad-spectrum effectiveness against a variety of bacteria, including both Gram-positive and Gram-negative species. It can therefore be used as an antibiotic to treat infections brought on by a variety of bacteria.
The global Macrolide Antibiotics market segmentation,based on Route of Administration, includesOral and Parenteral. The most money was made in the oral category (65.4%). The segment's expansion in the market is being fueled by convenience, cost, high patient compliance, and ease of administration.
The global Macrolide Antibiotics market segmentation, based on Indication, includes Infection Due to Mycoplasma Pneumoniae, Legionella Sp, or Bordetella Pertussis, Symptomatic Cat-Scratch Disease, Bacillary Angiomatosis, PeliosisHepatis in Patients with AIDS, Cerebral Toxoplasmosis, Uncomplicated Skin Infections, and Others. The category with the highest revenue was Cerebral Toxoplasmosis (35.4%). Clinical and radiological improvement is often shown within 10 to 14 days of therapy, and this is what is primarily driving the market's segmentation growth.
The global Macrolide Antibiotics market segmentation, based on End User, includes Hospitals, Dermatology Clinics, Pharmaceutical Companies, and Others. Due to the widespread use of macrolides for the treatment of hospital acquired infections, the Hospital category produced the largest revenue (41.4%). Growing populations of aged individuals who are prone to various illnesses increase the need for medical services, which in turn enhances the demand for goods and increases healthcare expenditures.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Insights into the markets in North America, Europe, Asia-Pacific, and the rest of the world are provided by the study.The North America Macrolide Antibiotics Marketdominated this market in 2022 (45.80%).The region's high demand for and consumption of antibiotics, particularly macrolides, is a contributing factor to this. The second most often prescribed antibiotic class in the US is the macrolide family, yet incorrect medication is rife, according to research on outpatient macrolide antibiotic prescribing in the US.Further, In the North American area, the U.S. Macrolide Antibiotics market had the biggest market share, while the Canada Macrolide Antibiotics market had the quickest rate of expansion.
Further, the major countries studiedin the market reportare The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
EuropeMacrolide Antibiotics market accounts for the second-largest market share. This is due to the fact that when infectious illness prevalence increases, so does the demand for antibiotics. Further, In the European region, the German Macrolide Antibiotics market had the biggest market share, and the U.K. Macrolide Antibiotics market had the quickest rate of growth.
The Asia-Pacific Macrolide Antibiotics Market is expected to grow at the fastest CAGR from 2023 to 2032. growing awareness of the availability of these medicines and rising healthcare spending. Furthermore, it is anticipated that the favorable reimbursement policies in Japan will boost the country's sales of macrolide antibiotics. Moreover, In the Asia-Pacific region, the Indian Macrolide Antibiotics market had the quickest rate of growth while China's Macrolide Antibiotics market had the greatest market share.
Leading industry companies are making significant R&D investments in order to diversify their product offerings, which will drive the Macrolide Antibiotics market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants are also engaging in a number of strategic actions to increase their global footprint. The Macrolide Antibiotics sector needs to provide affordable products if it wants to grow and thrive in a more competitive and challenging market environment.
One of the primary business strategies employed by manufacturers in the worldwide Macrolide Antibiotics industry to assist customers and expand the market sector is local manufacturing to reduce operational costs. Some of the biggest benefits to medicine have recently come from the Macrolide Antibiotics sector. Major players in the Macrolide Antibiotics market, including Merck Sharp &Dohme Corp (U.S.), Pfizer Inc. (U.S.), Neo Química (Brazil), Macrolide Pharmaceuticals (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi USA (U.S.), Sandoz International GmbH (Germany), Gland Pharma Limited (India), Mylan N.V. (U.S.), WOCKHARDT (U.S.), and Others are attempting to increase market demand by investing in research and development operations.
Merck Sharp &Dohme Corp. is a division of Merck & Co., Inc. It is a sizable healthcare system that provides state-of-the-art medical services. Outside of North America and Canada, Merck Sharp &Dohme Corp. is also known as MSD. This is one of the major pharmaceutical industries in the world. The business Merck Sharp &Dohme Corp. discovers, creates, and offers medications, vaccines, and other healthcare products for both people and animals. One of the studies in which Merck Sharp &Dohme Corp. took part examined the immunogenicity of the rVSV-G-ZEBOV-GP Ebola vaccine based on the post hoc analysis of three phase 2/3 trials. One of the medical devices developed by Merck Sharp &Dohme Corp. is the autoinjector pen. Merck Sharp &Dohme Corp. Federal Credit Union offers a variety of financial services to customers, including both individuals and corporations.
Pfizer Inc., a biopharmaceutical company founded on research, discovers, develops, produces, promotes, distributes, and sells biopharmaceutical products on a global scale. Two German businessman, Charles Pfizer and his relative Charles F. Erhart, founded Pfizer in New York in 1849. Pfizer's headquarters are in Manhattan, New York City, at The Spiral. For a variety of medical disorders, including oncology, rare diseases, internal medicine, immunizations, inflammation and immunology, and consumer healthcare, Pfizer offers medications and vaccines
· Merck Sharp &Dohme Corp (U.S.)
· Pfizer Inc. (U.S.)
· Neo Química (Brazil)
· Macrolide Pharmaceuticals (U.S.)
· Teva Pharmaceutical Industries Ltd. (Israel)
· Fresenius Kabi USA (U.S.)
· Sandoz International GmbH (Germany)
· Gland Pharma Limited (India)
· Mylan N.V. (U.S.)
· WOCKHARDT (U.S.)
April 2021: Pfizer acquired Amplyx Pharmaceuticals and its antifungal medication fosmanogepix.
February 2021: Sandoz signed a deal to acquire GSK's cephalosporin division in order to keep its position as the antibiotics market leader. The collaboration exemplifies Sandoz's commitment to growing its antibiotics business.
· Azithromycin
· Clarithromycin
· Erythromycin
· Fidaxomicin
· Telithromycin
· Oral
· Parenteral
· Infection Due to Mycoplasma Pneumoniae
· Legionella Sp, or Bordetella Pertussis
· Symptomatic Cat-Scratch Disease
· Bacillary Angiomatosis
· PeliosisHepatis in Patients with AIDS
· Cerebral Toxoplasmosis: Clinical and radiological improvement is usually seen within 10 to 14 days of therapy.
· Uncomplicated Skin Infections
· Others
· Hospitals
· Dermatology Clinics
· Pharmaceutical Companies
· Others
· North America
- U.S.
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
|
Report Attribute/Metric |
Details |
|
Market Size 2022 |
USD 50.7 Billion |
|
Market Size 2023 |
USD 57.67 Billion |
|
Market Size 2032 |
USD 154.33 Billion |
|
Compound Annual Growth Rate (CAGR) |
13.20% (2023-2032) |
|
Base Year |
2022 |
|
Market Forecast Period |
2023-2032 |
|
Historical Data |
2018- 2022 |
|
Market Forecast Units |
Value (USDBillion) |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Drugs, Route of Administration, Indication, End User, and Region |
|
Geographies Covered |
North America, Europe, AsiaPacific, and the Rest of the World |
|
Countries Covered |
The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
|
Key Companies Profiled |
Merck Sharp &Dohme Corp (U.S.), Pfizer Inc. (U.S.), Neo Química (Brazil), Macrolide Pharmaceuticals (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi USA (U.S.), Sandoz International GmbH (Germany), Gland Pharma Limited (India), Mylan N.V. (U.S.), WOCKHARDT (U.S.). |
|
Key Market Opportunities |
Development of novel macrolide antibiotics with improved efficacy and safety profiles |
|
Key Market Dynamics |
Increasing prevalence of skin infections, Growing demand for drugs against bacterial skin infections, and rapid expansion of antibiotics |
The global Macrolide Antibiotics market size was valued at USD50.7Billion in 2022.
The global market is projected to grow at a CAGR of 13.20% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Merck Sharp &Dohme Corp (U.S.), Pfizer Inc. (U.S.), Neo Química (Brazil), Macrolide Pharmaceuticals (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi USA (U.S.), Sandoz International GmbH (Germany), Gland Pharma Limited (India), Mylan N.V. (U.S.), WOCKHARDT (U.S.).
The azithromycin category dominated the market in 2022
The Hospitals segmenthad the largest share in the global market.
Research on the market is done by industry professionals who provide personalized insights on the industry structure, market segmentation, Type assessment, competitive landscape (CL), along with penetration, and emerging trends. In addition to years of professional experience in their various fields and sectors, their analysis is largely based on primary interview (60%) and secondary research (40%) as well as years of professional experience. In addition, our researchers forecast the market's direction over the following seven years by examining past trends and the market's current position. Additionally, various trends of segments and categories that are geographically portrayed are studied and estimated using primary and secondary research.
The key level executives (VP, CEO, Marketing Directors, and Business Development Managers) of the major industry participants who are active and prominent as well as mid-scale businesses operating in this market were interviewed in-depth for this supply-side report by overall Global Market Research.
Extensive primary research was conducted to gain a deeper grasp of the market and industry. Both primary and secondary research, as well as years of pertinent professional experience, are used to support the analysis. By analyzing past and present market patterns, our experts were able to forecast the market's course over the following seven years. For the geographically offered categories in the list of market tables, it differs per category. In connection with the Global Market research report, we also conducted a number of primary interviews with senior level executives (VP, CEO's, Directors, Marketing Directors, Business Development Managers, CFOs, Technical Consultants, Key Opinion Leaders, Industry Experts, Decision Matrix Authorities, and other crucial individuals) of the key industry players who dominated the Global market.
The primary purpose of secondary research was to gather, identify, and validate the information necessary for the thorough, technical, market-focused, and commercial analysis of the global market. With the use of this study, it was also possible to classify and segment the market in accordance with market trends, geographic markets, and regional considerations linked to market type. Analysts have gathered data in the Distribution Channel for the study of the market from reliable sources including annual reports, journals, white papers, corporate presentations, company websites, international organizations of Energy and Power manufacturers, credible paid databases, and many others to gather reliable intel.
Both top-down and bottom-up methodologies were employed to assess the accuracy of the global market size. The market for as a whole was estimated using these methods for a number of different dependent submarkets. Secondary research was used to address the major industry players, and primary and secondary research was used to calculate their market shares in the various regions. This complete intellectual process includes reading the annual and financial reports of the top market participants and conducting in-depth interviews with top industry executives (VP, CEO, Marketing Directors, and Business Development Managers) to gain important industry insights.
Through reliable secondary sources and validated primary sources, the classification of the global markets and their geographic percentage splits were established. To obtain the final qualitative and quantitative data, all relevant variables that might have an impact on the market under investigation have been taken into consideration, inspected in great depth, verified through primary research, and assessed. This information was collected, added to, and thoroughly examined by professional analysts before being provided in this report. The process used to estimate the overall market size for this study is depicted in the following image as an example.
Report Code :
RL65320
Published on :
Sep 2023
Request a Free Sample Report
Speak to Analyst